Inovalon, Boehringer team for outcomes-based deals
The Avalere Health LLC unit of Inovalon Holdings Inc. (NASDAQ:INOV) said it will work with Boehringer Ingelheim GmbH (Ingelheim, Germany) to track and analyze real-world outcomes for patients taking the pharma's diabetes drug Jardiance empagliflozin.
Avalere President Dan Mendelson told BioCentury that Inovalon will provide Boehringer with its database of over 150 million patient lives, which the partners will analyze to identify how patients taking Jardiance perform in the real world relative to other sodium-glucose cotransporter 2 (SGLT2) inhibitors. Based on the analyses, Avalere will develop optimization protocols that will allow the partners to intervene if patients are not responding as expected or are not adhering to the treatment protocol. ...